Russ Conroy

Investigators of the phase 2 MOMENTUM trial will enroll and assign approximately 100 patients to receive cemsidomide at 100 µg.

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

Although AI can be effective in hematologic malignancies and palliative care, it must be used ethically, said Ram Prakash Thirugnanasambandam, MBBS.

The new living guideline contains updated recommendations for biomarker testing and therapeutic strategies based on factors such as PD-L1 expression status.

Data from the EXCALIBER-RRMM trial support the application for iberdomide plus standard therapy in this relapsed/refractory multiple myeloma population.

Monthly dosing of subcutaneous amivantamab may confer consistent outcomes with the previously approved biweekly dosing schedule in EGFR-mutant NSCLC.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Investigators will share detailed results from the phase 3 LIBRETTO-432 trial assessing selpercatinib in NSCLC at a future medical meeting.

Data from the phase 1/2 CADENZA trial support pivekimab sunirine as a potential standard treatment for this rare blood cancer population.

Developing small molecules that target t(4;14) will be important in multiple myeloma care, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

New guidelines highlight asparaginase as a cornerstone of frontline therapy for adolescents and young adults with acute lymphoblastic leukemia.

Updated results from the TRIDENT-1 trial support repotrectinib as a new treatment option for those with NTRK fusion-positive advanced solid tumors.

In the future, the multiple myeloma field may gradually shift away from a continuous therapy model to more fixed-duration approaches.

Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

From key clinical trial updates to reports on treatment disparities, the 2026 Tandem Meetings saw several critical developments in multiple myeloma.

Older age appeared to correlate with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.

Global analysis data reveal that lung, stomach, and cervical cancers represent approximately half of preventable cancers.

Research may support the development of more comprehensive risk-stratification models accounting for different tumor-intrinsic factors.

Infusing chemoimmunotherapy earlier in the day also correlated with improvements in responses among patients with NSCLC in a phase 3 trial.

Potential FDA approval of teclistamab plus daratumumab may offer another option in the multiple myeloma armamentarium, said Surbhi Sidana, MD.

An unadjusted indirect comparison analysis of the SEQUOIA and AMPLIFY trials revealed improved PFS with zanubrutinib vs acalabrutinib plus venetoclax.

Investigators are currently assessing QTX-2101 among patients with acute promyelocytic leukemia in a phase 3 trial.

The FDA has assigned a Prescription Drug User Fee Act date of November 14, 2026, for the ivonescimab-based combination.

Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.

A new guideline from ASCO and Ontario Health conditionally recommends the use of daratumumab for patients with high-risk smoldering multiple myeloma.

Data from the phase 3 CEPHEUS trial support the approval of the daratumumab-based regimen among patients with newly diagnosed multiple myeloma.

Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.

Data from the ENDURE trial may contextualize prior evidence suggesting an interferon-related improvement in treatment-free remission rates in CML.

Findings show that age also represents an important driver for select pathologic genomic events differing at the presentation of disease by sex.